Working… Menu

Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03081780
Recruitment Status : Completed
First Posted : March 16, 2017
Last Update Posted : March 12, 2021
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

Brief Summary:
This is a Phase I open-label dose escalation study of a single infusion of FATE-NK100 and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy (CY/FLU) in subjects with refractory or relapsed acute myelogenous leukemia (AML). FATE-NK100 is a natural killer (NK) cell product that is enriched for NK cells with an "adaptive", or human cytomegalovirus (CMV)-induced, phenotype. The NK cell product is comprised of peripheral blood (PB) leukocytes sourced from a related donor (HLA-haploidentical or better but not fully HLA-matched) that is seropositive for cytomegalovirus (CMV+), and enriched for adaptive NK cells by depletion of CD3+ (T-lymphocytes) and CD19+ (B-lymphocytes) cells followed by ex-vivo culture expansion.

Condition or disease Intervention/treatment Phase
Refractory Acute Myelogenous Leukemia Relapsed Acute Myelogenous Leukemia Biological: FATE-NK100 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Actual Study Start Date : April 27, 2017
Actual Primary Completion Date : August 1, 2020
Actual Study Completion Date : December 1, 2020

Arm Intervention/treatment
Experimental: FATE NK-100 Biological: FATE-NK100

Preparative regimen:

  • Fludarabine 25 mg/m2 x 5 days start Day -6
  • Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4

Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12.

Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) [ Time Frame: 3 months ]
    Maximum FATE-NK100 dose which could be given to 3 participants such that not more than 1 participant experienced a DLT.

Secondary Outcome Measures :
  1. Clinical activity by CR/CRp leukemia clearance [ Time Frame: Day +42 ]
    Incidence of CRp defined as leukemia clearance (≤5%marrow blasts and no circulating peripheral blasts)

  2. Clinical activity by CR/CRp neutrophil recovery [ Time Frame: Day +42 ]
    Incidence of CRp defined as neutrophil recovery (ANC >500 cells/microliter) but with incomplete platelet recovery

  3. In vivo expansion of NK cells [ Time Frame: Day +14 ]
    Incidence of in vivo expansion (≥ 100 donor derived NK cells per uL blood) of NK cells

  4. Treatment Related Mortality (TRM) [ Time Frame: 6 months ]
    Incidence of treatment related mortality (TRM)

  5. Minimal residual disease (MRD) by bone marrow morphology [ Time Frame: up to Day 28 ]
    Incidence of minimal residual disease (MRD) clearance by bone marrow morphology after NK Cell infusion

  6. Minimal residual disease (MRD) by flow cytometry [ Time Frame: up to Day 28 ]
    Incidence of minimal residual disease (MRD) clearance by flow cytometry after NK Cell infusion

  7. Leukemia free survival (LFS) [ Time Frame: 1 year ]
    Incidence of Leukemia free survival (LFS)

  8. Overall survival (OS) [ Time Frame: 1 year ]
    Incidence of overall survival (OS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- ≥18 but ≤ 70 years of age

  • Diagnosis of acute myeloid leukemia (AML) and meets one of the following disease criteria:

    * Primary induction failure:

    ** De Novo AML: no CR after 2, 3 or 4 induction attempts with high dose chemotherapy

    • Secondary AML (from MDS or treatment related): no CR after 1, 2 or 3 cycles of high dose chemotherapy

      • Relapsed:
    • Not in CR after 1 or 2 cycles of standard re-induction therapy
    • Relapse diagnosed at the time of the 6 months post-HCT standard of care follow-up or later (i.e. based on bone marrow biopsy performed Day +170 or later) and without evidence of graft versus host disease (GVHD)

      • For patients > 60 years of age, the minimum of 1 cycle of standard chemotherapy is not required.
  • Available HLA-matched or better but not fully HLA-matched (2/4 or 3/4 antigens) related donor (aged 18 to 75 years) with donor/recipient match based on a minimum of intermediate resolution DNA based Class I typing of the A and B locus who is CMV seropositive.
  • Karnofsky Performance Status ≥ 60%
  • Adequate organ function within 14 days of study registration (28 days for pulmonary and cardiac) defined as:

    • Creatinine: Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min/1.73m^2 per current institutional calculation formula
    • Hepatic: AST and ALT ≤ 3 x upper limit of institutional normal
    • Pulmonary Function: oxygen saturation ≥ 90% on room air; PFT's required only if symptomatic or prior known impairment - must have pulmonary function >50% corrected DLCO and FEV1
    • Cardiac Function: LVEF ≥ 40% by echocardiography or MUGA
    • No symptomatic active conduction system abnormalities
  • Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to FATE-NK100 cell infusion (excluding preparative regimen premedications)
  • Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy
  • Voluntary written consent prior to the performance of any research related procedures

Arm Specific Inclusion Criteria

High-Risk aGVHD (ARM 1):

- Pediatric or adult (ages 0-76 years) HCT recipients with high-risk acute GVHD, as determined either by the refined MN acute GVHD risk score [28]: OR high risk on the basis of blood biomarkers (Ann Arbor Score 3) [31]. Patients in this arm must start treatment within the first 7 days after onset of high-risk aGVHD.


Steroid- Dependent aGVHD (ARM 2A):

- Pediatric or adult (ages 0-76 years) HCT recipient with grade II-IV steroid-dependent acute GVHD, defined as any one of the following: Flare of acute GVHD of at least grade II/IV severity within 8 weeks of tapering down or (off of) immunosuppression for acute GVHD, with the flare occurring on ≤0.5 mg/kg prednisone. This can include late-onset aGVHD and overlap syndrome.


Steroid-Refractory aGVHD (ARM 2B):

- Pediatric or adult (ages 0-76 years) HCT recipient with grade II-IV steroid refractory acute GVHD, defined as any one of the following:

  • No response of acute GVHD after at least 4 days of systemic corticosteroids of at least 2 mg/kg prednisone or equivalent
  • Progression of acute GVHD within 3 days of systemic corticosteroids of at least 2 mg/kg prednisone or equivalent
  • Failure to improve to at least grade II acute GVHD after 14 days of systemic corticosteroids, with initial doses of at least 2 mg/kg prednisone or equivalent
  • Flare of acute GVHD of at least grade II/IV severity while on steroids at a dose >0.5/mg/kg/day. This can include late-onset aGVHD and overlap syndrome.

Exclusion Criteria:

  • Myocardial Infraction (MI) within the previous 6 months
  • Acute leukemias of ambiguous lineage
  • Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. Women of child bearing potential must have a negative pregnancy test at screening
  • History of or known active CNS involvement with AML
  • Active autoimmune disease requiring systemic immunosuppressive therapy
  • History of severe asthma and currently on chronic systemic medications (mild asthma requiring inhaled steroids only is eligible)
  • New or progressive pulmonary infiltrates on screening chest X-ray or chest CT scan unless cleared for study by Pulmonary. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections).
  • Uncontrolled bacterial, fungal or viral infections including HIV-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
  • Received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03081780

Layout table for location information
United States, Minnesota
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Layout table for investigator information
Principal Investigator: Murali Janakiram, MD, MS University of Minnesota
Layout table for additonal information
Responsible Party: Masonic Cancer Center, University of Minnesota Identifier: NCT03081780    
Other Study ID Numbers: 2016LS153
First Posted: March 16, 2017    Key Record Dates
Last Update Posted: March 12, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Masonic Cancer Center, University of Minnesota:
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type